Search

Victor N Sakran

Examiner (ID: 15805)

Most Active Art Unit
3507
Art Unit(s)
3507, 3505, 3677, 3626, 2899
Total Applications
3429
Issued Applications
3196
Pending Applications
92
Abandoned Applications
141

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17274505 [patent_doc_number] => 20210380703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/394228 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17394228 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/394228
ACVR2A-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF Aug 3, 2021 Abandoned
Array ( [id] => 17213146 [patent_doc_number] => 20210346482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => SUBSTANCES, VACCINES AND METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF TRANSPLANT REJECTION [patent_app_type] => utility [patent_app_number] => 17/380477 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18957 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17380477 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/380477
SUBSTANCES, VACCINES AND METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF TRANSPLANT REJECTION Jul 19, 2021 Abandoned
Array ( [id] => 17214563 [patent_doc_number] => 20210347900 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => ANTIBODIES SPECIFIC FOR LOX1 AND USE IN TREATMENT OF CARDIOVASCULAR DISORDERS [patent_app_type] => utility [patent_app_number] => 17/377863 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50132 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17377863 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/377863
ANTIBODIES SPECIFIC FOR LOX1 AND USE IN TREATMENT OF CARDIOVASCULAR DISORDERS Jul 15, 2021 Abandoned
Array ( [id] => 19187852 [patent_doc_number] => 20240166765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/015532 [patent_app_country] => US [patent_app_date] => 2021-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 89629 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015532 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/015532
INFLAMMATORY DISEASE TREATMENT USING ANTI-TISSUE FACTOR ANTIBODIES Jul 9, 2021 Pending
Array ( [id] => 18628251 [patent_doc_number] => 20230287105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-14 [patent_title] => METHODS FOR TREATING CARDIOVASCULAR DISEASE [patent_app_type] => utility [patent_app_number] => 18/015444 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31999 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18015444 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/015444
METHODS FOR TREATING CARDIOVASCULAR DISEASE Jul 8, 2021 Pending
Array ( [id] => 17369975 [patent_doc_number] => 20220025027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/305413 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305413 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/305413
ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF Jul 6, 2021 Abandoned
Array ( [id] => 17369974 [patent_doc_number] => 20220025026 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/305412 [patent_app_country] => US [patent_app_date] => 2021-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305412 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/305412
ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF Jul 6, 2021 Abandoned
Array ( [id] => 19396171 [patent_doc_number] => 12070500 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-27 [patent_title] => Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis [patent_app_type] => utility [patent_app_number] => 17/362020 [patent_app_country] => US [patent_app_date] => 2021-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 30131 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17362020 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/362020
Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis Jun 28, 2021 Issued
Array ( [id] => 17443811 [patent_doc_number] => 20220064316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR [patent_app_type] => utility [patent_app_number] => 17/359211 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 121885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17359211 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/359211
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor Jun 24, 2021 Issued
Array ( [id] => 17154820 [patent_doc_number] => 20210315871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => METHODS FOR TREATING AORTIC VALVE STENOSIS WITH A HEDGEHOG PATHWAY INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/354648 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5429 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17354648 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/354648
METHODS FOR TREATING AORTIC VALVE STENOSIS WITH A HEDGEHOG PATHWAY INHIBITOR Jun 21, 2021 Abandoned
Array ( [id] => 18770885 [patent_doc_number] => 20230365687 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => ANTI-CD2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/012089 [patent_app_country] => US [patent_app_date] => 2021-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61199 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012089 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/012089
ANTI-CD2 ANTIBODIES Jun 21, 2021 Pending
Array ( [id] => 18672955 [patent_doc_number] => 20230310409 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => TREATING RHEUMATOID ARTHRITIS [patent_app_type] => utility [patent_app_number] => 18/011884 [patent_app_country] => US [patent_app_date] => 2021-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18011884 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/011884
TREATING RHEUMATOID ARTHRITIS Jun 20, 2021 Pending
Array ( [id] => 17990205 [patent_doc_number] => 20220356242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/348949 [patent_app_country] => US [patent_app_date] => 2021-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 117463 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17348949 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/348949
NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE Jun 15, 2021 Abandoned
Array ( [id] => 18717874 [patent_doc_number] => 11795205 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Heterodimeric Relaxin fusions polypeptides [patent_app_type] => utility [patent_app_number] => 17/348825 [patent_app_country] => US [patent_app_date] => 2021-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 11 [patent_no_of_words] => 16061 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17348825 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/348825
Heterodimeric Relaxin fusions polypeptides Jun 15, 2021 Issued
Array ( [id] => 17482275 [patent_doc_number] => 20220089779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => NME INHIBITORS AND METHODS OF USING NME INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/306477 [patent_app_country] => US [patent_app_date] => 2021-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29001 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306477 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/306477
NME INHIBITORS AND METHODS OF USING NME INHIBITORS May 2, 2021 Abandoned
Array ( [id] => 17665311 [patent_doc_number] => 11358992 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Cell-penetrating cereblon recombinant fusion protein and use thereof [patent_app_type] => utility [patent_app_number] => 17/244975 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 6269 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17244975 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/244975
Cell-penetrating cereblon recombinant fusion protein and use thereof Apr 29, 2021 Issued
Array ( [id] => 18552151 [patent_doc_number] => 20230250160 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => BISPECIFIC PROTEIN [patent_app_type] => utility [patent_app_number] => 17/997270 [patent_app_country] => US [patent_app_date] => 2021-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17997270 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/997270
BISPECIFIC PROTEIN Apr 28, 2021 Pending
Array ( [id] => 17168878 [patent_doc_number] => 20210322548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => METHODS AND COMPOSITIONS RELATING TO TREATMENT OF PULMONARY ARTERIAL HYPERTENSION [patent_app_type] => utility [patent_app_number] => 17/239983 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17976 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17239983 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/239983
Method for treating fibrosis with an anti-GDF-15 antibody Apr 25, 2021 Issued
Array ( [id] => 17185252 [patent_doc_number] => 20210332137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => COMBINATION THERAPY FOR CANCER [patent_app_type] => utility [patent_app_number] => 17/224865 [patent_app_country] => US [patent_app_date] => 2021-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23583 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224865 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/224865
COMBINATION THERAPY FOR CANCER Apr 6, 2021 Pending
Array ( [id] => 18337261 [patent_doc_number] => 20230129210 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => BINDING PROTEINS USEFUL AGAINST ACE2-TARGETED VIRUSES [patent_app_type] => utility [patent_app_number] => 17/914000 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28240 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914000 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/914000
BINDING PROTEINS USEFUL AGAINST ACE2-TARGETED VIRUSES Apr 4, 2021 Pending
Menu